false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Autosom ...
Screening and Management of ADPKD-Related Intracra ...
Screening and Management of ADPKD-Related Intracranial Aneurysms
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Terry Wotnik reviewed screening and management of intracranial aneurysms in autosomal dominant polycystic kidney disease (ADPKD). Unruptured aneurysms occur in about 13% of patients—four to five times the general-population rate—while rupture remains uncommon in absolute terms but can cause severe disability or death. A family history of aneurysm or subarachnoid hemorrhage, particularly in a first-degree relative, is the strongest screening risk factor; smoking is also important.<br /><br />KDIGO recommends educating all adults with ADPKD about aneurysm risks and involving them in shared decisions. Screening is recommended for people with a personal history of subarachnoid hemorrhage or a relevant family history, and may be considered with unknown family history, before transplantation or major surgery, and in other higher-risk circumstances. Screening may also be offered to anyone who chooses it after discussing benefits and harms. Time-of-flight MRA is generally preferred, especially in chronic kidney disease; CTA is an alternative.<br /><br />After a negative scan, repeat screening every 5–10 years may be appropriate for high-risk individuals, with timing individualized. Detected aneurysms require multidisciplinary assessment. Options include risk-factor control and imaging surveillance, surgical clipping, or endovascular treatment, depending on aneurysm features and patient risk. Further prospective research is needed to clarify screening intervals, rupture risks, and genetic and environmental factors.
Asset Caption
Terry J. Watnick, MD
Meta Tag
Speaker
Terry Watnick
Keywords
autosomal dominant polycystic kidney disease
intracranial aneurysm
subarachnoid hemorrhage
aneurysm screening
family history
time-of-flight MRA
endovascular treatment
×
Please select your language
1
English